Kaleido Biosciences in Research Collaboration with Janssen

By Michael Dabaie

Kaleido Biosciences Inc. (KLDO) said it initiated a research collaboration with Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos.

The companies will look at the potential for Kaleido's Microbiome Metabolic Therapies, or MMTs, to prevent the onset of childhood allergy and other atopic, immune and metabolic conditions. The agreement was facilitated by Johnson & Johnson Innovation, Kaleido said.

A primary focus of the research will be to utilize Kaleido's screening platform to identify MMTs candidates that support the growth of specific beneficial microbes. These MMTs will then be further evaluated for their ability to prevent atopic conditions such as infant allergy, Kaleido said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

January 09, 2020 08:43 ET (13:43 GMT)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024